GST-π、ERCC1、MRP和LRP在卵巢癌组织中的表达及意义  

Expression and clinical significance of GST-π,ERCC1,MRP and LRP in human epithelial ovarian carcinoma

作　　者：梁梦[1] 周英琼[1] 郭芳[1] 侯巧燕[1] 许连静[1] 李莎莎[1] 

机构地区：[1]桂林医学院附属医院病理科,广西桂林541001

出　　处：《中国现代医学杂志》2012年第5期10-14,共5页China Journal of Modern Medicine

基　　金：广西教育厅科研资助项目(No:201012MS173)

摘　　要：目的探讨谷胱甘肽S-转移酶π(GST-π)、切除修复交叉互补基因(ERCC1)、多药耐药相关蛋白(MRP)及肺耐药相关蛋白(LRP)在上皮性卵巢癌组织中的表达及临床意义。方法采用免疫组织化学技术检测67例卵巢恶性肿瘤、20例卵巢良性肿瘤和16例正常卵巢组织中GST-π、ERCC1、MRP及LRP的表达状况,并对相关的临床病理因素进行分析。结果①67例卵巢癌中,GST-π、MRP和LRP阳性表达均显著高于其在卵巢良性肿瘤和正常卵巢组织中的阳性表达(P<0.05),而ERCC1的阳性表达同卵巢良性肿瘤和正常卵巢组织比较差异无统计学意义(P>0.05)。②GST-π的表达与肿瘤分化程度有关,分化越低表达越高(P<0.05);而ERCC1、MRP和LRP的阳性表达与多种临床病理因素无关(P>0.05)。结论 GST-π、ERCC1、MRP及LRP蛋白在卵巢癌的发生发展及耐药机制中发挥重要作用,联合检测对卵巢癌治疗方案的合理制定及化疗反应性的评估具有积极的临床指导意义。[Objective] To investigate the expression and clinical significance of the glutathione S- tranferases-π （GST-π）, excision repair cross-complement gene l （ERCC1） muhidrug resistance-related protein （MRP） and lung resistance-related protein （LRP） in human ovarian carcinoma and evaluate it＇s roles in chemoresistance of ovarian carcinoma. [Methods] The expression of GST-π, ERCC1, MRP and LRP in 67cases of ovarian cancer, 20 cases of ovarian benign tumors and 16 cases of normal controls was determined by using immunohistochemical method and the results were studied in correlation with some clinical and pathological data. [Results] The positive expression rate of GST-π, MRP and LRP in ovarian carcinoma was significantly higher than in benign tumors and normal tissues （P 〈0.05）; A significant relationship was shown the expression of GST-π and pathologic grade as well as clinical stage respectively （P 〈0.05）. [ Conclusion ] Co-detection of GST-π, ERCC1, MRP and LRP expression can be used to select reasoned chemotherapy regimens, predict the chemotherapeutic response, and evaluate the prognosis of ovarian carcinoma patients.

关 键 词：卵巢癌 谷胱甘肽S-转移酶π 修复交叉互补基因1 多药耐药相关蛋白 肺耐药相关蛋白 化疗 

分 类 号：R737.31[医药卫生—肿瘤]